Thursday, Sanofi SA (NASDAQ:SNY) reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on constant currency. The French drugmaker reported adjusted EPS of $0.97 (1.78 euros), beating the consensus estimate of $0.94. Also Read: In Heart Burn Drug Zantac’s Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster. The company reported first-quarter sales of $11.36 billion (10.5 billion euros), beating the consensus of $11.04 billion. Research and Development expenses increased by 10.0% to 1.7 billion euros. At CER, R&D expenses increased by 11.8%, reflecting increased expenses in Vaccines ...